Category Archives: MS Treatment

CTVNews.ca Staff Published Monday, September 9, 2013 3:41PM EDT Last Updated Monday, September 9, 2013 8:11PM EDT Canadians who were among multiple sclerosis sufferers waiting to take part in a clinical trial into the so-called liberation treatment were disappointed on Monday by news that the trial was cancelled. The Saskatchewan government was told that the Albany Medical Centre in New York has stopped its trial into the effectiveness of angioplasty in treating CCSVI (chronic cerebro-spinal venous insufficiency) and relieving symptoms of multiple sclerosis. The treatment involves opening blocked neck veins. There were 86 planned participants from Saskatchewan -- a province home to one of the highest rates of M.S. sufferers compared to the rest of Canada. The province had committed up to $2.2 million to have its patients participate in the Albany study. Clinical trial lead Dr. Gary Siskin told Saskatchewans Ministry of Health that he wasnt able to meet the overall target enrolment needed for the study to meet U.S. government requirements for a clinical trial. Siskin told CTV News that hes very disappointed the trial had to be cancelled. He spoke about the difficulty in getting people to enrol in the study, as participants seemed reluctant because of … Continue reading →

Dallas, Texas (PRWEB) September 08, 2013 The global multiple sclerosis therapeutics market has the potential to grow to a value of $17.9 billion by 2019. The market is currently led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 20122019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. Scope of the report Multiple Sclerosis Therapeutics to 2019 Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth (http://www.rnrmarketresearch.com/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-market-report.html) covers: A brief introduction to MS, including the diseases history, pathogenesis, risk factors and diagnosis. In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat … Continue reading →

Denver, Colorado (PRWEB) September 05, 2013 According to the Natural Multiple Sclerosis Treatment review available on http://www.SclerosisTreatment.com, the home treatment was created by a famous American surgeon, Dr. Gary M. Levin. SclerosisTreatment.com reveals that Dr. Gary M. Levin spent many years trying to find a cure for Multiple Sclerosis. His research proved to be a success when he discovered a unique combination of herbal remedies and natural treatments that can lead to permanent healing. The cure will be achieved quickly and its results are permanent, Dr. Gary M. Levin claims. SclerosisTreatment.com writes that this new MS natural treatment is as safe as possible. Any patient, regardless of his age, overall health or moment of diagnose can try this natural treatment. The home remedy has no contraindications or potential harmful effects on health. All the recommendations Dr. Gary M. Levin shares with his patients can be implemented at home. Consequently, patients can forget all about endless visits to their physicians office. What makes this natural treatment such an efficient cure of multiple sclerosis is actually the fact that it first targets the root cause of this disease. When the underlying cause of multiple sclerosis is found and cured, the patient will … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 650,000 shares of its common stock, at a price to the public of $1.50 per share, in connection with the Companys recently announced underwritten public offering of 12,000,000 shares of common stock, bringing total gross proceeds from the offering to $18,975,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Aegis Capital Corp. acted as sole book-running manager for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 7, 2013. The offering was made only by means of a prospectus. Copies of the prospectus relating to the offering are available on the SECs website at http://www.sec.gov. Copies of the prospectus may also be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18thFloor, New York, NY, 10019, via telephone at (212) 813-1010, or via email at prospectus@aegiscap.com. This press release does not constitute an offer to … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, Opexas President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held September 8-10th at The Millennium Broadway Hotel in New York City. Opexas presentation will occur at 2:50 p.m. (EDT) on Tuesday, September 10, 2013 in Room 7.04 of The Millennium Broadway Hotel and will include an overview of the Companys ongoing clinical development program for Tcelna, the Companys lead therapy for MS. The presentation will be webcast and the link to access the audio webcast and presentation will be available on the Investor Relations page of the Companys website at http://www.opexatherapeutics.com. About Opexa Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy currently in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells isolated from the patients peripheral blood, expanded ex … Continue reading →

SAN DIEGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl L. Hilleman has been appointed chief financial officer effective September 3, 2013. Ms. Hilleman will replace Dana McGowan who will continue with the company during a transition period in which the company plans to move its headquarters to Northern California. "I am very pleased that an executive with Jeri's skills, global experience and proven expertise is joining our senior management team," said Linda Grais, M.D., president and chief executive officer of Ocera. "Her extensive public company experience, both in and outside of the biotech industry, combined with her operational leadership, will be invaluable as we execute on our immediate business priority to initiate a Phase 2b clinical trial of OCR-002 for the treatment of acute hepatic encephalopathy. I would also like to thank Dana McGowan for her many contributions and years of dedication to Ocera." "Ocera has the potential to transform both acute and chronic treatment of critical liver conditions, with significant potential to save lives," said Jeri Hilleman. "The opportunity to join Ocera to help realize this potential is exciting and … Continue reading →

PBR Staff Writer Published 03 September 2013 Drug discovery and development firm Apitope has completed its second Phase I clinical trial of ATX-MS-1467 with positive results. When patients with relapsing multiple sclerosis were treated with intradermal injection of ATX-MS-1467, the MRI results showed a decrease in the number of contrast-enhancing brain lesions (CEL). The positive results allow Merck Serono with whom Apitope is developing ATX-MS-1467 to advance its Phase II plans. Apitope CEO Keith Martin said," The results of this trial in patients with relapsing MS continue to build on the positive data from our first study and provide further clinical support for the Apitope approach to the treatment of serious autoimmune conditions." Apitope's ATX-MS-1467 treatment is aimed at working with the immune system to treat the underlying cause of disease and restoring immunological balance, rather than just treating the symptoms or suppressing the complete immune system. Apitope CSO and founder David Wraith said antigen specific immunotherapy is designed to correct the immunological imbalance that causes autoimmune disease without inducing the non-specific immune suppression that so frequently causes unacceptable side effects. "Up to now this approach has been shown to be highly effective in experimental models but has been slow … Continue reading →

BRISTOL, Englad & HASSELT, Belgium--(BUSINESS WIRE)-- Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467. Examination of the MRI results (new Gd and total Gd enhancing lesions) demonstrated a significant decrease in the number of contrast-enhancing brain lesions (CEL) in patients with relapsing multiple sclerosis treated by intradermal injection of ATX-MS-1467. The same effect was not seen in the subcutaneously dosed group. These encouraging results will now need confirmation in appropriate Phase II trials. Completion of the study together with these positive MRI-based data allows Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, with whom Apitope is developing ATX-MS-1467, to develop plans for Phase II onwards. Dr. Keith Martin, CEO of Apitope stated: We are pleased to have successfully completed a challenging clinical trial with positive results. The results of this trial in patients with relapsing MS continue to build on the positive data from our first study and provide further clinical support for the Apitope approach to the treatment of serious autoimmune conditions. Prof David Wraith, Apitopes CSO and Founder added: Antigen specific immunotherapy is … Continue reading →

In view of rising accidents atDahi Handicelebrations,Cholamandalam MS General Insurance Company Ltd. (Chola MS), the leading provider of insurance products and services, had launched a special safety initiative for Govinda revelers yesterday. As a one of its kind initiative, the company extended backup ambulances and medical support to about 550dahi handiparticipants across 30 locations in Mumbai. As a first response rescue, the ambulances were equipped with doctors and attendants along-with emergency first-aid medical kits and oxygen cylinders. This initiative helped 12 Govindas receive timely treatment from the available doctors on board. The participants were from Trimurty Yuva Mandal and Kalubhai Govinda. This was part of the insurance majors corporate social responsibility (CSR) initiative. The past couple of years have seen a steep rise in casualties during theJanmashtamicelebrations. The height of thedahi handipyramids are eight-tiers and more. A fall from this height can be fatal. It is our endeavor to reduce the risk or at the very least create a safety net in the event of an accident. This is our way of saying that we are there when you need us the most, says Mr.Neeraj Moorjani, Head Marketing, Chola MS. Dahi Handiis a traditional sport held in celebration of the … Continue reading →

CHERRY HILL, N.J., Aug. 27, 2013 /PRNewswire/ --The Multiple Sclerosis Association of America (MSAA) is pleased to announce new website additions including an MS Relapse Resource Center and chat feature to its award-winning website, mymsaa.org. As a leading resource for the entire multiple sclerosis (MS) community, MSAA developed these additions to provide easier access to vital information and assistance to individuals with MS, their care partners, and healthcare professionals. (Logo: http://photos.prnewswire.com/prnh/20120620/PH27981LOGO ) The MS Relapse Resource Center provides detailed information on MS relapses and treatment options to help individuals with MS better understand relapses and how to best manage them. The MS Relapse Resource Center contains four main sections: In addition, MSAA has introduced an interactive one-on-one chat feature that allows individuals to have a live conversation with an experienced Client Services Consultant. All of MSAA's Client Services Consultants are Master's level social work and counseling professionals. They are available to assist individuals with MS by identifying and explaining programs offered by MSAA. They can also refer individuals to other resources and information that may be of help. "I am proud of the strides MSAA has taken to provide valuable information and services to the entire MS community," states MSAA … Continue reading →